Benefits of gastric bypass surgery In a recent report about the long term benefits of gastric bypass surgery good results were still being seen 12 years post-operative, an observational study found. People with severe obesity who underwent Roux-en-Y gastric bypass reported a sustained body weight reduction 12 years following surgery (-77.2 lbs from baseline, 95 change -26.9 follow-up rate at 12-years, the analysis included 1,156 severely obese patients — 418 of whom underwent Roux-en-Y gastric bypass. Comprising of two nonsurgical comparative groups, there were 417 patients who sought out surgery, but did not undergo surgery mainly due to insurance coverage (non-surgery group 1). ‘Nonsurgery group 2’ comprised of a total of 321 severely obese people, who did not seek out surgery. All nonsurgery participants were not provided with any study-based weight loss therapy, however, they were free to independently pursue such intervention. After 12 years, neither nonsurgery group achieved a significant mean change in weight loss: Group 1: -6.4 lbs (-15.2 to -2.2, mean change -2.0) Two years after gastric bypass, the surgery group reported a significant adjusted mean body weight change of -99.2 lbs from baseline (95 ). Similar benefits were also seen at 6 years out of surgery, with a sustained loss of -80.0 lbs mean body weight change from baseline (95 of surgery patients with type 2 diabetes achieved remission (66 of 88), and 62), with Adams calling this finding “encouraging.” The odds ratio for incidence diabetes versus nonsurgery 1 was 0.08 (95 CI 0.03-0.29)(P<0.001 for both). Rates of diabetes remission were largely predicted by therapies used at baseline. Surgery patients who were not receiving antidiabetic medications as baseline were more likely to achieve remission after surgery (73 CI 46-99, 16 of 22), while 56 CI 35-77, 24 of 43). Only 16 CI -8 to 39, three of 19). However, even in surgery patients who did not achieve remission, a significant improvement was still reported after 12 years, with a decreased mean in the amount of antidiabetic medications compared to both nonsurgery group 1 (-0.3± versus 0.8, P=0.002) and nonsurgery group 2 (-0.3 versus 1.1, P<0.001). Several cardiovascular-related benefits were also reported after 12 years among the surgery group, with significant remission rates reported for HDL cholesterol, LDL cholesterol, and triglyceride levels compared to both nonsurgical groups. Long term hypertension benefit was also reported following surgical
Read more…
